It still has to be approved in the EU and I have no doubt it will be approved anytime soon. But the company has no plans to commercialize it in the UK.
Comments
May 18: At this time Otsuka has no plans to commercialise Rexulti in the UK [18].Apr 17: Filed in EU via centralised procedure [17].
I wonder what the real reason is?
Do you have any idea @YoungSchizo?
@Wave I did a quick search but there’s no news about it, maybe the reason wil come later in the press… However, since this announcement is coming from UK’s ‘FDA’ site, it’s legit.
Comments
May 18: recommended for EU approval by CHMP - full indication is “the treatment of schizophrenia in adult patients” [19]
It will be called Rxulti in Europe
It is a new ap? @YoungSchizo
@anon73425833 yes and no. It’s a improved version of Abilify from the same company that made Abilify. The mechanism of action differs a little bit and therefore it should have less (serious) side-effects than Abilify.
It’s still is considered a second generation antipsychotic, which means that it does not treat cognitive or negative symptoms effectively better than any drug already available.